These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35506893)

  • 1. Synthetic studies on the indane SHIP1 agonist AQX-1125.
    Dungan OM; Dormann S; Fernandes S; Duffy BC; Effiong DG; Kerr WG; Chisholm JD
    Org Biomol Chem; 2022 May; 20(19):4016-4020. PubMed ID: 35506893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.
    Nickel JC; Egerdie B; Davis E; Evans R; Mackenzie L; Shrewsbury SB
    J Urol; 2016 Sep; 196(3):747-54. PubMed ID: 26968644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Chernoff D; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1519-29. PubMed ID: 23121409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Wu J; Ogden N; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1506-18. PubMed ID: 23121445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
    Leaker BR; Barnes PJ; O'Connor BJ; Ali FY; Tam P; Neville J; Mackenzie LF; MacRury T
    Clin Exp Allergy; 2014 Sep; 44(9):1146-53. PubMed ID: 25040039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.
    Cross J; Stenton GR; Harwig C; Szabo C; Genovese T; Di Paola R; Esposito E; Cuzzocrea S; Mackenzie LF
    Br J Pharmacol; 2017 Sep; 174(18):3045-3057. PubMed ID: 28658529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the SHIP1 Pathway Fails to Show Treatment Benefit in Interstitial Cystitis/Bladder Pain Syndrome: Lessons Learned from Evaluating Potentially Effective Therapies in This Enigmatic Syndrome.
    Nickel JC; Moldwin R; Hanno P; Dmochowski R; Peters KM; Payne C; Wein A
    J Urol; 2019 Aug; 202(2):301-308. PubMed ID: 31090511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling.
    Xie X; Hu L; Mi B; Panayi AC; Xue H; Hu Y; Liu G; Chen L; Yan C; Zha K; Lin Z; Zhou W; Gao F; Liu G
    Front Cell Dev Biol; 2022; 10():826023. PubMed ID: 35445030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of SHIP1 in cancer and mucosal inflammation.
    Fernandes S; Iyer S; Kerr WG
    Ann N Y Acad Sci; 2013 Mar; 1280(1):6-10. PubMed ID: 23551094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Activity Studies on Bis-Sulfonamide SHIP1 Activators.
    Meyer ST; Fernandes S; Anderson RE; Pacherille A; Toms B; Kerr WG; Chisholm JD
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice.
    Park MY; Srivastava N; Sudan R; Viernes DR; Chisholm JD; Engelman RW; Kerr WG
    Mucosal Immunol; 2014 Nov; 7(6):1429-1439. PubMed ID: 24781051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
    Ong CJ; Ming-Lum A; Nodwell M; Ghanipour A; Yang L; Williams DE; Kim J; Demirjian L; Qasimi P; Ruschmann J; Cao LP; Ma K; Chung SW; Duronio V; Andersen RJ; Krystal G; Mui AL
    Blood; 2007 Sep; 110(6):1942-9. PubMed ID: 17502453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHIP1 Deficiency in Inflammatory Bowel Disease Is Associated With Severe Crohn's Disease and Peripheral T Cell Reduction.
    Fernandes S; Srivastava N; Sudan R; Middleton FA; Shergill AK; Ryan JC; Kerr WG
    Front Immunol; 2018; 9():1100. PubMed ID: 29872435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of SHIP1 in bone biology.
    Iyer S; Margulies BS; Kerr WG
    Ann N Y Acad Sci; 2013 Mar; 1280():11-4. PubMed ID: 23551095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of SHIP1 in T-lymphocyte life and death.
    Gloire G; Erneux C; Piette J
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):277-80. PubMed ID: 17371259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of SHIP1 in Invariant NKT Cell Development and Functions.
    Anderson CK; Salter AI; Toussaint LE; Reilly EC; Fugère C; Srivastava N; Kerr WG; Brossay L
    J Immunol; 2015 Sep; 195(5):2149-2156. PubMed ID: 26232432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth.
    Séverin S; Gratacap MP; Lenain N; Alvarez L; Hollande E; Penninger JM; Gachet C; Plantavid M; Payrastre B
    J Clin Invest; 2007 Apr; 117(4):944-52. PubMed ID: 17347685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of SHIP via a small molecule agonist kills multiple myeloma cells.
    Kennah M; Yau TY; Nodwell M; Krystal G; Andersen RJ; Ong CJ; Mui AL
    Exp Hematol; 2009 Nov; 37(11):1274-83. PubMed ID: 19703514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.
    Fuhler GM; Brooks R; Toms B; Iyer S; Gengo EA; Park MY; Gumbleton M; Viernes DR; Chisholm JD; Kerr WG
    Mol Med; 2012 Feb; 18(1):65-75. PubMed ID: 22033675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
    An H; Xu H; Zhang M; Zhou J; Feng T; Qian C; Qi R; Cao X
    Blood; 2005 Jun; 105(12):4685-92. PubMed ID: 15701712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.